Journal of Thoracic Oncology

Papers
(The H4-Index of Journal of Thoracic Oncology is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community893
Meeting Announcements433
EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study345
P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy261
EP08.02-027 T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC253
P45.14 Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China240
P37.03 The Epidemic of Malignant Mesothelioma in China: A Prediction of Incidence During 2016-2030228
In This Issue/Research Watch/News in Brief225
Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib213
In This Issue/Research Watch/News in Brief205
213P Development of an explainable clinical decision support tool for advanced lung cancer patients197
218P Implications of the eighth edition of TNM staging system for thymoma, a single-center retrospective study196
EP07.01-024 Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma195
EP07.03-001 Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma185
P30.02 Salvage Surgery in Patients With Locally Advanced Non-Small Cell Lung Cancer – Outcomes and Longtime Results175
P33.01 Air Leak Due COVID-19 in a Lung Cancer Patient150
EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy137
115P Salvage surgery in patients with locally advanced or metastatic non-small cell lung cancer134
P10.09 Efficacy and Toxicity of EGFR-TKI in Frail NSCLC with EGFR Mutation: A Retrospective Analysis in a Single Institution127
P12.01 A Novel 89Zr-α-PD-1 Immuno-PET-CT May Improve Pseudoprogression Detection in a Lung Cancer Murine Model Receiving Immunotherapy127
EP05.01-023 Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial126
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC125
P23.02 Digital Multiplexed circRNA Analysis From Plasma-Derived Extracellular Vesicles of Lung Cancer Patients122
EP08.01-055 Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer115
EP08.01-079 Long Term Use of Immune Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer (NSCLC) and Abnormal Marrow Pathology: A Case Series112
EP08.01-093 ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer112
P66.08 Differential Expression of INSM1 Between Pure SCLC and LCNEC After Surgical Resection and Its Clinicopathological Significance110
EP14.02-006 Subtype-specific Hypersensitivity to Oxidative Phosphorylation Inhibition in Small Cell Lung Cancer109
EP16.03-018 Molecular Features of Subtypes Classified Based on Predominance and Components in Chinese Patients with Lung Adenocarcinoma104
OA11.06 Sequencing of ctDNA Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis102
P66.06 GPNMB Associates With Inferior Prognosis in SCLC Patients Through Promoting Tumor Cell Metastasis96
MA04.09 The Incidence and Predictors of Unsuspected Brain Metastases in Patients with Stage IA NSCLC95
EP14.05-019 Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-202194
P68.06 Development and Validation of an NGS-Based MSI Detection Method90
FP02.01 Utilization and Refusal of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: A National Cancer Database Study90
Table of Contents88
FP01.02 A Comparative Cost Analysis Study of Robotic and Video-Assisted Lobectomy: Results of Randomized Controlled Trial (Bravo Trial)85
EP01.01-007 Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients84
EP11.03-004 Identification of Filigree Pattern Increases Diagnostic Accuracy of Micropapillary Pattern on Frozen Section for Lung Adenocarcinoma81
EP01.02-006 Excuse Me? Patient Perceptions of Lung Cancer Screening Results81
73P Qualitative research to evaluate perceptions around biomarker testing and patient-reported outcomes (PROs) for use in studies of non-small cell lung cancer (NSCLC)80
63P Inflammatory indexes and treatment response as correlates of pembrolizumab effectiveness in patients with PD-L1≥50%: Data from the real-life practice80
P68.18 Relationship Between Cholesterol Synthesis in Cancer Cells and Anticancer Effect of Statins79
MA02.05 A Phase I Study of Afatinib in Combination With Osimertinib in Patients After Failure of Prior Osimertinib79
EP01.07-001 Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial79
P06.08 Treatment Outcome of Second Primary Lung Cancer77
PP.04 EGFR Structure-Based Classification and Presence of Commutations in Peruvian Patients With Advanced Lung Cancer77
OA10.04 COVID-19 Vaccine Acceptance and Communications Effectiveness Amongst Canadian Lung Cancer Patients.76
50P Patient-reported outcomes in non-small cell lung cancer patients receiving immunotherapy monotherapy: Analysis from enhanced, EHR-facilitated cancer symptom control (E2C2) pragmatic clinical trial74
25P Furmonertinib plus icotinib for first-line treatment of EGFR-mutated non-small cell lung cancer73
P2.07-01 Deep-Learning Based Prediction of c-MET Status from Digitized H&E-Stained Non-Small Cell Lung Cancer Tissue Samples73
EP04.01-012 Sex and Age-Related Guideline-Adherence Disparities in Non-Small-Cell Lung Cancer Treatment Patterns: Real-World Data73
OA08.06 Implementation of a Nurse-led Geriatric Oncology Assessment Model in the Lung Cancer Care Pathway71
European Society of Thoracic Surgeons (ESTS)70
P07.03 Lung Cancer Under 50 Years Old – What Reality Taught Us69
EP04.01-001 Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience69
MA02.01 Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial69
FP14.01 A Phase 1b/2 Study of Autologous Dendritic Cell Vaccination in Combination With Atezolizumab in Patients With Small Cell Lung Cancer (SCLC)69
P59.01 Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy66
EP08.02-119 RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer65
P61.05 Time to Loosen Up: Liberalizing Lung Cancer Screening Guidelines Might Save More Lives63
Table of Contents62
Preoperative Biopsy Diagnosis in Patients With Pulmonary Carcinoids: A Biomarker Panel Will Be Crucial to Hit a Bull’s Eye62
P34.04 Chemo-Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Real World Data from a Tertiary Oncology Centre62
0.18442106246948